Maura L. Gillison's HPV research transforms cancer treatment

Research conducted by Dr. Maura L. Gillison has fundamentally transformed the medical understanding of head and neck cancers by identifying Human Papillomavirus (HPV), specifically HPV-16, as a primary driver of oropharyngeal cancers.

For decades, throat cancers were predominantly attributed to smoking and alcohol consumption. Dr. Gillison's work, including significant findings published in The Journal of the National Cancer Institute and The New England Journal of Medicine, proved that HPV causes a biologically distinct form of cancer affecting the throat, tonsils, and base of the tongue. This distinction is critical because HPV-positive tumors behave differently than those linked to tobacco and alcohol.

This scientific shift has led to major changes in clinical practice, including the development of specific staging systems, the implementation of less toxic treatment protocols, and the integration of HPV vaccination into central cancer prevention policies. In the United States, research suggests that approximately 73% of head and neck cancers are now related to HPV infection.